Page 55 - Read Online

Casadei et al. J Cancer Metastasis Treat 2022;8:21 https://dx.doi.org/10.20517/2394-4722.2022.05 Page 17 of 19

39. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy,
prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des
Lymphomes de l'Adulte. J Clin Oncol 1997;15:1110-7. DOI PubMed
40. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with
follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101-6. DOI PubMed
41. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for
patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet
2013;381:1203-10. DOI PubMed
42. Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of
indolent NHL or MCL: the BRIGHT study. Blood 2014;123:2944-52. DOI PubMed PMC
43. Flinn IW, van der Jagt R, Kahl B, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell
Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. J Clin
Oncol 2019;37:984-91. DOI PubMed PMC
44. Moccia AA, Taverna C, Schär S, et al. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the
SAKK 35/03 randomized trial. Blood Adv 2020;4:5951-7. DOI PubMed PMC
45. Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated
Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol 2018;36:2395-404.
DOI PubMed
46. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's
lymphoma. J Clin Oncol 2003;21:3051-9. DOI PubMed
47. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-
Hodgkin's lymphoma. J Clin Oncol 2005;23:5044-51. PubMed
48. Leonard JP, Schuster SJ, Emmanouilides C, et al. Durable complete responses from therapy with combined epratuzumab and
rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer
2008;113:2714-23. DOI PubMed
49. Grant BW, Jung SH, Johnson JL, et al. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated
follicular lymphoma: CALGB 50701. Cancer 2013;119:3797-804. DOI PubMed PMC
50. Morschhauser F, Fowler NH, Feugier P, et al; RELEVANCE Trial Investigators. Rituximab plus Lenalidomide in Advanced
Untreated Follicular Lymphoma. N Engl J Med 2018;379:934-47. DOI PubMed
51. Bachy E, Houot R, Feugier P, et al. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need
of systemic therapy: a LYSA study. Blood 2022;139:2338-46. DOI PubMed
52. Luminari S, Manni M, Galimberti S, et al; Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular
Lymphoma: The FOLL12 Study.
J Clin Oncol 2022;40:729-39. DOI PubMed
53. Dreyling M, Ghielmini M, Rule S, et al; Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for
diagnosis; treatment and follow-up.
Ann Oncol 2021;32:298-308. DOI PubMed
54. Montoto S, Corradini P, Dreyling M, et al. Indications for hematopoietic stem cell transplantation in patients with follicular
lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica 2013;98:1014-21. DOI PubMed PMC
55. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-
Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010;116:106-14. DOI PubMed PMC
56. Rueda A, Calvo V, Casanova M, et al. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients
with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group. Leuk
Lymphoma 2019;60:1576-9. DOI PubMed
57. Sehn LH, Goy A, Offner FC, et al. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With
Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol 2015;33:3467-74.
DOI PubMed PMC
58. Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results
of the GAUDI study (BO21000). Blood 2013;122:1137-43. DOI PubMed
59. Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-
refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet
Oncol 2016;17:1081-93. DOI PubMed
60. Cheson BD, Chua N, Mayer J, et al. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin
Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J
Clin Oncol 2018;36:2259-66. DOI PubMed
61. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular
lymphoma. J Clin Oncol 2005;23:4390-8. DOI PubMed
62. Leonard JP, Friedberg JW, Younes A, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with
rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;18:1216-23. DOI PubMed